Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2) | Synapse
April 16, 2021Open Access
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
Key Points
Key points are not available for this paper at this time.
Abstract
The safety, tolerability, and effectiveness of berotralstat were maintained over 48 weeks of treatment.